These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27928961)

  • 1. DARPins Bioengineering and its Theranostic Approaches: Emerging Trends in Protein Engineering.
    Rasool M; Malik A; Hussain M; Haq KA; Butt K; Ashraf MAB; Naseer MI; Asif M; Shaikh R; Mustafa MZ; Alam Q; Rasool G; Ahmad W; Haque A; Kamal MA
    Curr Pharm Des; 2017; 23(11):1610-1615. PubMed ID: 27928961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Application of Designed Ankyrin Repeat Proteins (DARPins) as Research Tools and Protein Therapeutics.
    Boersma YL
    Methods Mol Biol; 2018; 1798():307-327. PubMed ID: 29868969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designed ankyrin repeat proteins (DARPins) from research to therapy.
    Tamaskovic R; Simon M; Stefan N; Schwill M; Plückthun A
    Methods Enzymol; 2012; 503():101-34. PubMed ID: 22230567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DARPins: a new generation of protein therapeutics.
    Stumpp MT; Binz HK; Amstutz P
    Drug Discov Today; 2008 Aug; 13(15-16):695-701. PubMed ID: 18621567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designed ankyrin repeat proteins (DARPins) as novel isoform-specific intracellular inhibitors of c-Jun N-terminal kinases.
    Parizek P; Kummer L; Rube P; Prinz A; Herberg FW; Plückthun A
    ACS Chem Biol; 2012 Aug; 7(8):1356-66. PubMed ID: 22568706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries.
    Amstutz P; Koch H; Binz HK; Deuber SA; Plückthun A
    Protein Eng Des Sel; 2006 May; 19(5):219-29. PubMed ID: 16551653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.
    Zahnd C; Kawe M; Stumpp MT; de Pasquale C; Tamaskovic R; Nagy-Davidescu G; Dreier B; Schibli R; Binz HK; Waibel R; Plückthun A
    Cancer Res; 2010 Feb; 70(4):1595-605. PubMed ID: 20124480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural determinants for improved stability of designed ankyrin repeat proteins with a redesigned C-capping module.
    Kramer MA; Wetzel SK; Plückthun A; Mittl PR; Grütter MG
    J Mol Biol; 2010 Dec; 404(3):381-91. PubMed ID: 20851127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display.
    Steiner D; Forrer P; Plückthun A
    J Mol Biol; 2008 Oct; 382(5):1211-27. PubMed ID: 18706916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display.
    Schilling J; Schöppe J; Plückthun A
    J Mol Biol; 2014 Feb; 426(3):691-721. PubMed ID: 24513107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy.
    Plückthun A
    Annu Rev Pharmacol Toxicol; 2015; 55():489-511. PubMed ID: 25562645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the relationship between sequences, structures, dynamical behaviors and functions of new type protein drugs: DARPins.
    Wu X; Shi Y; Ren P; Wang D; Li G
    Curr Pharm Des; 2013; 19(12):2308-17. PubMed ID: 23082980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DARPins: a true alternative to antibodies.
    Stumpp MT; Amstutz P
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):153-9. PubMed ID: 17436550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designed ankyrin repeat proteins as anti-idiotypic-binding molecules.
    Vogel M; Keller-Gautschi E; Baumann MJ; Amstutz P; Ruf C; Kricek F; Stadler BM
    Ann N Y Acad Sci; 2007 Aug; 1109():9-18. PubMed ID: 17785285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential applications of designed ankyrin repeat proteins in diagnostics and therapeutics.
    Baumann MJ; Stadler BM; Vogel M
    Expert Opin Med Diagn; 2007 Nov; 1(3):409-21. PubMed ID: 23489359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries.
    Simon M; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2012 Feb; 23(2):279-86. PubMed ID: 22188139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro selection and characterization of DARPins and Fab fragments for the co-crystallization of membrane proteins: The Na(+)-citrate symporter CitS as an example.
    Huber T; Steiner D; Röthlisberger D; Plückthun A
    J Struct Biol; 2007 Aug; 159(2):206-21. PubMed ID: 17369048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection and characterization of Her2 binding-designed ankyrin repeat proteins.
    Zahnd C; Pecorari F; Straumann N; Wyler E; Plückthun A
    J Biol Chem; 2006 Nov; 281(46):35167-75. PubMed ID: 16963452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency.
    Stefan N; Martin-Killias P; Wyss-Stoeckle S; Honegger A; Zangemeister-Wittke U; Plückthun A
    J Mol Biol; 2011 Nov; 413(4):826-43. PubMed ID: 21963989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DARPin-Based Crystallization Chaperones Exploit Molecular Geometry as a Screening Dimension in Protein Crystallography.
    Batyuk A; Wu Y; Honegger A; Heberling MM; Plückthun A
    J Mol Biol; 2016 Apr; 428(8):1574-88. PubMed ID: 26975886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.